Gilead Sciences (GILD) Long-Term Debt Issuances (2009 - 2026)
Gilead Sciences' (GILD) quarterly Long-Term Debt Issuances came in at $1.3 billion in Q2 2026, up 14555.56% on a YoY basis from N/an in Q2 2025, and down 52.31% quarter-over-quarter from $2.8 billion in Q1 2026.
Analysis
Gilead Sciences (GILD) Long-Term Debt Issuances (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has reported Long-Term Debt Issuances for 18 consecutive years, with $1.3 billion the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Long-Term Debt Issuances rose 14555.56% year-over-year to $1.3 billion; the trailing twelve-month figure through Jun 2026 stood at $4.1 billion (up 21.22% YoY), and the FY2025 full-year result was $1.8 billion, down 48.38% from the prior year.
- Long-Term Debt Issuances slipped to $1.3 billion in Q2 2026 per GILD's latest filing, from $2.8 billion in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $2.8 billion in Q1 2026 and bottomed at $8.0 million in Q4 2025.
- Historically, Long-Term Debt Issuances has averaged $1.1 billion across 5 years, with a median of $1.2 billion in 2022.
- The sharpest annual moves came in 2025 and 2026: Long-Term Debt Issuances slumped 99.51% in 2025, then surged 14555.56% in 2026.
- Over 5 years, Long-Term Debt Issuances stood at $1.0 billion in 2022, then surged by 125.0% to $2.2 billion in 2023, then tumbled by 33.29% to $1.5 billion in 2024, then sank by 99.47% to $8.0 million in 2025, then jumped by 16387.5% to $1.3 billion in 2026.
- According to Business Quant data, Long-Term Debt Issuances over the past three periods registered $1.3 billion, $2.8 billion, and $8.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.51 Bn | 197.52 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.48 Bn | 178.30 Bn | 6.22 Bn | 1.32 Bn |
| 3 | Vertex Pharmaceuticals | 132.45 Bn | 124.60 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.72 Bn | 49.59 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.31 Bn | 30.31 Bn | 1.16 Mn | - |
| 10 | Insmed | 28.19 Bn | 27.03 Bn | 358.27 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.32 Bn |
| Mar 31, 2026 | 2.77 Bn |
| Dec 31, 2025 | 8.00 Mn |
| Sep 30, 2025 | 9.00 Mn |
| Jun 30, 2025 | 9.00 Mn |
| Mar 31, 2025 | 1.76 Bn |
| Dec 31, 2024 | 1.50 Bn |
| Sep 30, 2024 | 112.00 Mn |
| Jun 30, 2024 | 1.85 Bn |
| Sep 30, 2023 | 2.25 Bn |
| Sep 30, 2022 | 1.00 Bn |
| Mar 31, 2022 | 500.00 Mn |
| Dec 31, 2021 | 1.00 Bn |
| Sep 30, 2021 | 2.50 Bn |
| Mar 31, 2021 | 1.25 Bn |
| Dec 31, 2020 | 995.00 Mn |
| Sep 30, 2020 | 6.69 Bn |
| Mar 31, 2020 | 500.00 Mn |
| Sep 30, 2019 | 1.50 Bn |
| Jun 30, 2019 | 500.00 Mn |